Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer's disease

Nelleke Tolboom*, Maqsood Yaqub, Ronald Boellaard, Gert Luurtsema, Albert D. Windhorst, Philip Scheltens, Adriaan A. Lammertsma, Bart N. M. van Berckel

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

63 Citations (Scopus)

Abstract

Purpose The aim of this study was to assess the test-retest variability of [(11)C] PIB studies in patients with Alzheimer's disease (AD) and healthy controls using several tracer kinetic models and to assess the suitability of the cerebellum as reference tissue.

Methods [(11)C]PIB studies with arterial sampling were performed in eight AD patients and eight healthy controls. Retest scans were performed in six controls and six AD patients. Data were analysed using plasma input and reference tissue models, together with simple ratios.

Results Test-retest variability was best (similar to 3%) for SRTM2, a parametric method based on the simplified reference tissue model. Highest values (similar to 10%) were found for plasma input models. Cerebellar V(T) values did not differ significantly between AD and controls.

Conclusion Parametric SRTM2 with the cerebellum as reference tissue is the method of choice for quantitative analysis of [(11)C]PIB PET studies.

Original languageEnglish
Pages (from-to)1629-1638
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume36
Issue number10
DOIs
Publication statusPublished - Oct-2009
Externally publishedYes

Keywords

  • Pittsburgh compound B
  • PIB
  • Arterial sampling
  • Cerebellum
  • Parametric images
  • Amyloid
  • PET
  • PITTSBURGH COMPOUND-B
  • REFERENCE TISSUE MODEL
  • AMYLOID DEPOSITION
  • SENILE PLAQUES
  • HUMAN BRAIN
  • BINDING
  • NEURORECEPTOR
  • CEREBELLUM
  • RECEPTOR

Fingerprint

Dive into the research topics of 'Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this